EXACT Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model
Oslo, Norway and Mountain View, CA, 28 January 2025. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, and Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz.
The combination of ACT and the device may offer potential applications across a wide range of brain diseases, by enabling therapeutic access to large brain regions. The combined technologies can induce bioeffects, such as temporarily increasing blood-brain barrier permeability in targeted regions and increasing the uptake of therapeutic agents. ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.
“The combination of the Cordance technology and the ACT microcluster technology from Exact Therapeutics provides exciting possibilities for accessing and opening larger volumes in the brain without necessarily increasing the focused ultrasound procedure time or the total amount of ultrasound energy,” said Dr. Bhaskar Ramamurthy Cofounder and CEO of Cordance Medical.
“These positive results in glioblastoma provide additional early evidence of the versatility of the noninvasive ACT microcluster technology in cancer therapy. Oncology is the key focus for Exact Therapeutics, spearheaded by our ongoing Phase 2 trial in locally advanced pancreatic cancer, which received IND clearance at the end of 2024.”, said Dr. Per Walday, CEO of Exact Therapeutics.
About Cordance Medical
Cordance Medical specializes in innovative, non-invasive solutions for treating brain diseases. The company’s flagship NeuroAccess™ platform is designed to enable precise, targeted treatment options, improving patient outcomes worldwide.
About Exact Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com